CJC No DAC (Mod GRF 1-29) — GHRH Analog

CJC No DAC is commonly used shorthand for CJC-1295 without DAC, more accurately aligned with Mod GRF 1-29 (a stabilized GHRH(1-29) analog). In research discussions it is used to increase growth hormone (GH) pulsatility, especially when paired with a GHRP such as ipamorelin.

Research Use Disclaimer: This content is for educational research discussion only and not medical advice. Mod GRF 1-29 / “CJC no DAC” products are not FDA-approved for anti-aging or bodybuilding. Use in humans without clinical oversight carries significant unknowns.

Description

Endogenous growth hormone–releasing hormone (GHRH) from the hypothalamus stimulates pituitary somatotrophs to release GH in pulses. Mod GRF 1-29 is a modified fragment of GHRH designed to resist enzymatic degradation, often discussed in research communities for short-acting, pulse-supportive GH release.

Potential Research Benefits

  • Enhanced GH pulse signaling (mechanistic rationale; depends on timing/food/sleep).
  • Synergy with GHRPs (e.g., ipamorelin) for larger GH pulses.
  • IGF-1 downstream signaling may increase over time depending on exposure and individual response.

Mechanism of Action

Mod GRF 1-29 binds the GHRH receptor on pituitary somatotrophs, activating cAMP signaling and promoting GH secretion. In gut–brain axis terms, it’s primarily a neuroendocrine peptide (hypothalamus → pituitary), but peripheral metabolic state (glucose/insulin, free fatty acids) can influence GH secretion and somatostatin tone.

Side Effects (Reported / Theoretical)

  • Injection site irritation (if injected).
  • Flushing, headache (reported with some GHRH analogs).
  • Water retention, tingling (possible GH-axis related effects).
  • Potential effects on glucose handling with prolonged GH-axis manipulation (context-dependent).

Contraindications (Precautionary)

  • Pregnancy/breastfeeding (insufficient data).
  • Active malignancy or history of cancer (GH/IGF axis theoretical concern).
  • Uncontrolled diabetes/metabolic disease (monitoring complexity).

SubQ vs IM (If Injectable)

In research settings, Mod GRF 1-29 is most commonly administered SubQ. IM is less common and not clearly superior for short-acting microgram dosing.

Reconstitution and Dosing Math (Examples)

Reconstitute lyophilized powder with bacteriostatic water using aseptic technique.

2 mg vial example

Add 2.0 mL bac water → concentration = 1,000 mcg/mL.

  • 0.10 mL (10 IU) = 100 mcg
  • 0.15 mL (15 IU) = 150 mcg

5 mg vial example

Add 5.0 mL bac water → concentration = 1,000 mcg/mL.

  • 0.10 mL (10 IU) = 100 mcg
  • 0.15 mL (15 IU) = 150 mcg

Research Dosing (Common Informal Patterns)

Common non-clinical pattern discussed online: 100 mcg per dose, 2–3× daily, often paired with ipamorelin at the same injection times. Not clinically validated.

Stacking Suggestions

  • Ipamorelin: classic pairing to increase GH pulse amplitude (GHRH + GHRP synergy).
  • Sleep support: GH pulses are strongly tied to sleep quality/architecture.
  • Keep stacks simple; adding insulin sensitizers, thyroid agents, etc. increases confounders and risk.

Research Sources (PubMed)

  1. Seminal discovery of GHRH and endocrine function. Science. 1982. PMID: 6122015
  2. GHRH receptor and pituitary GH secretion physiology (review). Endocr Rev. 1999. PMID: 10337570
  3. Modified GRF (1-29) analogs and GH release in humans (pharmacology). J Clin Endocrinol Metab. 1995. PMID: 7714089
  4. GHRH and somatostatin interplay controlling GH pulsatility. Endocr Rev. 2000. PMID: 11041429
  5. GHRP + GHRH synergy in GH secretion (human endocrine study). J Clin Endocrinol Metab. 1994. PMID: 8175955
  6. Clinical evaluation of CJC-1295 (with DAC) and GH/IGF-1 elevation (context for naming confusion). J Clin Endocrinol Metab. 2006. PMID: 16492687
Scroll to Top